Who are Gimeracil and Oteracil Porassium Capsules's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Aubagio, Teriflunomide HMR1726, Leflunomide 10 milligram (MG), FLUNIXIN, Leflunomide plus Methotrexate, Leflunomide(LEF).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gimeracil-and-oteracil-porassium-capsules.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

Gimeracil and Oteracil Porassium Capsules — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gimeracil and Oteracil Porassium Capsules (Gimeracil and Oteracil Porassium Capsules) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Pyrimidine synthesis inhibitor. Area: Oncology.

phase 2 Pyrimidine synthesis inhibitor Dihydroorotate dehydrogenase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Gimeracil and Oteracil Porassium Capsules (Gimeracil and Oteracil Porassium Capsules) — Beijing Biohealthcare Biotechnology Co.,Ltd. Inhibits dihydroorotate dehydrogenase

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Gimeracil and Oteracil Porassium Capsules TARGET	Gimeracil and Oteracil Porassium Capsules	Beijing Biohealthcare Biotechnology Co.,Ltd	phase 2	Pyrimidine synthesis inhibitor	Dihydroorotate dehydrogenase
Aubagio	TERIFLUNOMIDE	Sanofi	marketed	Pyrimidine Synthesis Inhibitor [EPC]	dihydroorotate dehydrogenase	2012-01-01
Teriflunomide HMR1726	Teriflunomide HMR1726	Sanofi	marketed	Dihydroorotate dehydrogenase inhibitor; immunosuppressant	Dihydroorotate dehydrogenase (DHODH)
Leflunomide 10 milligram (MG)	Leflunomide 10 milligram (MG)	P. Verschueren	marketed	DHODH inhibitor; disease-modifying antirheumatic drug (DMARD)	Dihydroorotate dehydrogenase (DHODH)
FLUNIXIN	FLUNIXIN		marketed		Dihydroorotate dehydrogenase (quinone), mitochondrial
Leflunomide plus Methotrexate	Leflunomide plus Methotrexate	Bangladesh Medical University	marketed	Disease-modifying antirheumatic drug (DMARD) combination	Dihydroorotate dehydrogenase (leflunomide); Dihydrofolate reductase (methotrexate)
Leflunomide(LEF)	Leflunomide(LEF)	Nanjing Children's Hospital	marketed	Immunosuppressant; DHODH inhibitor	Dihydroorotate dehydrogenase (DHODH)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Pyrimidine synthesis inhibitor class)

Beijing Biohealthcare Biotechnology Co.,Ltd · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Gimeracil and Oteracil Porassium Capsules — Competitive Intelligence Brief. https://druglandscape.com/ci/gimeracil-and-oteracil-porassium-capsules. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab